Medincell says Teva raises 2026 UZEDY sales forecast to $290 million-$310 million
TEVA•Teva raised its 2026 UZEDY sales forecast to $290 million-$310 million from $270 million-$290 million. Third-quarter US net sales were $85 million, up 96% year over year, while nine-month sales reached $225 million.
1. UZEDY sales forecast
Teva raised its 2026 UZEDY sales forecast to $290 million-$310 million from $270 million-$290 million. Third-quarter US net sales reached $85 million, up 96% year over year, and nine-month sales totaled $225 million, exceeding full-year 2025 sales of $191 million. Medincell receives mid- to high-single-digit royalties on net sales and is eligible for $105 million in sales-based milestone payments.
